Dupilumab in the Treatment of Cheilitis in Atopic Dermatitis Patients

BACKGROUND/OBJECTIVES: The lip is a unique tissue type that acts as a “barrier” to the mouth and receives many external stimuli. It is also a common symptom in atopic dermatitis. Dupilumab was the first targeted biological drug approved for the treatment of moderate-to-severe atopic dermatitis (AD)....

Descripción completa

Detalles Bibliográficos
Autores principales: Shan, Jinpeng, Ali, Kamran, Da, Jiayang, Li, Menghua, Qiu, Yunmi, Lou, HaiYue, Wu, Liming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664921/
https://www.ncbi.nlm.nih.gov/pubmed/36387959
http://dx.doi.org/10.2147/CCID.S391944

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664921/
https://www.ncbi.nlm.nih.gov/pubmed/36387959
http://dx.doi.org/10.2147/CCID.S391944

Ejemplares similares